Comparing the current results to its competitors, Alpha Tau Medical Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Alpha Tau Medical Ltd's competitors' average revenue growth of 11.05 %, achieved in the same quarter.
Alpha Tau Medical Ltd's Comment on Competition and Industry Peers
The company faces competition from both established and early-stage companies, some of which collaborate, that often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Competition also exists in recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Competitors may develop treatments that are safer, more effective, have fewer side effects, are more convenient, less expensive, or have more favorable labeling than the company's Alpha DaRT technology. They may also obtain FDA or other regulatory approvals more rapidly, potentially securing a strong market position before the company can enter. Key competitive factors include efficacy, safety, convenience, ease of use, price, imaging diagnostics effectiveness, generic competition, and reimbursement availability. The only specific competitor product mentioned is Xofigo, approved in 2013 for bone metastases associated with prostate cancer.
October 10, 2024
CSIMarket.com October 10, 2024 In an exciting development for oncology, Alpha Tau Medical Ltd. announced today that it has treated its first patient with recurrent lung cancer using Alpha DaRT, a groundbreaking alpha-radiation therapy. This milestone was reached at the Hadassah Medical Center in Jerusalem, marking a significant step forward in the quest to provide effective treatments for challenging malignancies.Lung cancer, particularly in its recurrent form, poses a considerable treatment challenge due to its resilience and the limited efficacy of existing therapies. Conventional options often include chemotherapy, radiation, and surgical intervention, but the prognosis remains poor for many patients...
Introduction Alpha Tau Medical, a leading global developer of alpha radiation cancer therapy, has recently announced highly promising interim results from their safety and feasibility trial for the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) treatment in advanced pancreatic cancer patients. The interim data for this innovative therapy demonstrate successful administration in all five treated patients, with no product-related Serious Adverse Events reported. These remarkable findings provide new hope for patients suffering from this challenging cancer, emphasizing the potential efficacy and safety of Alpha DaRT in the fight against pancreatic cancer. Understanding Alpha DaRT Alpha...
Plus Therapeutics Inc is a biotechnology company that focuses on developing precision nanoparticles for targeted therapy. They utilize their proprietary technology to create and commercialize innovative drugs for the treatment of cancer and other diseases.
Sigyn Therapeutics Inc has a business model focused on developing novel medical therapeutics for the treatment of life-threatening inflammatory conditions.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Novocure Limited is a medical technology company that focuses on developing and commercializing innovative therapies for cancer treatment. The company's business model revolves around its proprietary treatment platform called tumor treating fields (TTFields), which uses electric fields to disrupt cancer cell division and inhibit tumor growth. Novocure operates by manufacturing and distributing its TTFields delivery system, while also conducting clinical trials and collaborating with healthcare providers to integrate its therapy into standard cancer care.
Sources:
Alpha Tau Medical Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alpha Tau Medical Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
